Clovis Oncology (NASDAQ:CLVS) had its price target lowered by equities researchers at HC Wainwright from $39.00 to $37.00 in a research note issued to investors on Monday, The Fly reports. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. HC Wainwright’s price target would indicate a potential upside of 57.58% from the stock’s previous close.

A number of other analysts have also recently weighed in on the company. ValuEngine cut Clovis Oncology from a “hold” rating to a “sell” rating in a research report on Wednesday, January 2nd. Zacks Investment Research cut Clovis Oncology from a “hold” rating to a “sell” rating in a research report on Thursday, January 3rd. BidaskClub raised Clovis Oncology from a “sell” rating to a “hold” rating in a research report on Wednesday, January 9th. Piper Jaffray Companies raised their price objective on Clovis Oncology to $23.00 and gave the stock a “neutral” rating in a research report on Wednesday, February 27th. Finally, JPMorgan Chase & Co. reissued a “hold” rating and issued a $27.00 price objective on shares of Clovis Oncology in a research report on Wednesday, February 27th. Two analysts have rated the stock with a sell rating, five have issued a hold rating and eight have assigned a buy rating to the stock. Clovis Oncology presently has a consensus rating of “Hold” and an average target price of $44.22.

Shares of NASDAQ CLVS opened at $23.48 on Monday. The company has a current ratio of 4.55, a quick ratio of 4.34 and a debt-to-equity ratio of 3.93. The firm has a market cap of $1.26 billion, a price-to-earnings ratio of -3.32 and a beta of 2.07. Clovis Oncology has a 12-month low of $11.50 and a 12-month high of $62.01.

Clovis Oncology (NASDAQ:CLVS) last announced its earnings results on Tuesday, February 26th. The biopharmaceutical company reported ($1.88) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.72) by ($0.16). The company had revenue of $30.40 million for the quarter, compared to the consensus estimate of $30.46 million. Clovis Oncology had a negative net margin of 385.80% and a negative return on equity of 147.39%. The firm’s revenue was up 78.4% compared to the same quarter last year. During the same period last year, the business posted ($1.04) EPS. As a group, equities research analysts expect that Clovis Oncology will post -7.06 EPS for the current year.

In related news, Director James C. Blair sold 17,056 shares of the firm’s stock in a transaction on Thursday, March 14th. The stock was sold at an average price of $27.79, for a total value of $473,986.24. Following the completion of the transaction, the director now owns 13,439 shares in the company, valued at approximately $373,469.81. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Lindsey Rolfe sold 1,731 shares of the firm’s stock in a transaction on Tuesday, March 5th. The stock was sold at an average price of $29.29, for a total value of $50,700.99. Following the completion of the transaction, the insider now owns 16,497 shares of the company’s stock, valued at approximately $483,197.13. The disclosure for this sale can be found here. Insiders sold a total of 20,782 shares of company stock valued at $576,755 in the last three months. Insiders own 10.20% of the company’s stock.

A number of hedge funds have recently modified their holdings of the stock. Teachers Advisors LLC raised its stake in Clovis Oncology by 0.9% in the 3rd quarter. Teachers Advisors LLC now owns 144,561 shares of the biopharmaceutical company’s stock worth $4,246,000 after acquiring an additional 1,278 shares during the last quarter. Great West Life Assurance Co. Can raised its stake in Clovis Oncology by 54.8% in the 4th quarter. Great West Life Assurance Co. Can now owns 7,034 shares of the biopharmaceutical company’s stock worth $122,000 after acquiring an additional 2,489 shares during the last quarter. Legal & General Group Plc raised its stake in Clovis Oncology by 29.9% in the 4th quarter. Legal & General Group Plc now owns 20,457 shares of the biopharmaceutical company’s stock worth $368,000 after acquiring an additional 4,711 shares during the last quarter. Pacer Advisors Inc. purchased a new position in Clovis Oncology in the 3rd quarter worth $226,000. Finally, Gabelli Funds LLC raised its stake in Clovis Oncology by 115.9% in the 4th quarter. Gabelli Funds LLC now owns 14,900 shares of the biopharmaceutical company’s stock worth $268,000 after acquiring an additional 8,000 shares during the last quarter.

About Clovis Oncology

Clovis Oncology, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Its commercial product includes Rubraca (rucaparib) tablet, a small molecule poly ADP-ribose polymerase inhibitor, used as monotherapy for the treatment of patients with deleterious BRCA mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca.

Featured Story: The benefits and drawbacks of dollar cost averaging

The Fly

Analyst Recommendations for Clovis Oncology (NASDAQ:CLVS)

Receive News & Ratings for Clovis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.